{"doi":"10.20411/pai.v10i1.752","title":"Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies","abstract":"Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized. Methods: We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines. Results: Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP3.3. Conclusions: Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.","journal":"Pathogens and Immunity","year":2024,"id":418822,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.952,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":863038,"name":"Isabelle Staropoli","orcid":"0000-0001-8637-4545","position":1,"is_corresponding":false},{"id":752016,"name":"Cyril Planchais","orcid":"0000-0002-5142-7253","position":2,"is_corresponding":false},{"id":887732,"name":"Emilie Yab","orcid":null,"position":3,"is_corresponding":false},{"id":1160582,"name":"Banujaa Jeyarajah","orcid":null,"position":4,"is_corresponding":false},{"id":862602,"name":"Yannis Rahou","orcid":null,"position":5,"is_corresponding":false},{"id":870127,"name":"Matthieu Prot","orcid":"0000-0003-2337-2491","position":6,"is_corresponding":false},{"id":870126,"name":"Florence Guivel‐Benhassine","orcid":"0000-0003-3410-5671","position":7,"is_corresponding":false},{"id":560702,"name":"Frédéric Lemoine","orcid":"0000-0001-9576-4449","position":8,"is_corresponding":false},{"id":1090558,"name":"Vincent Enouf","orcid":"0000-0001-7609-4742","position":9,"is_corresponding":false},{"id":621564,"name":"Etienne Simon‐Lorière","orcid":"0000-0001-8420-7743","position":10,"is_corresponding":false},{"id":417919,"name":"Hugo Mouquet","orcid":"0000-0002-4230-610X","position":11,"is_corresponding":false},{"id":1207380,"name":"Marie‐Anne Rameix‐Welti","orcid":"0000-0002-5901-3856","position":12,"is_corresponding":false},{"id":292388,"name":"Olivier Schwartz","orcid":"0000-0002-0729-1475","position":13,"is_corresponding":false},{"id":870125,"name":"Delphine Planas","orcid":"0000-0002-2509-9954","position":0,"is_corresponding":true}],"reference_count":17,"raw_metadata":null,"created_at":"2026-07-19T01:57:09.067930Z","pmid":"39391808","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}